Clinical Trials Logo

Malignant Neoplasm clinical trials

View clinical trials related to Malignant Neoplasm.

Filter by:

NCT ID: NCT03228147 Completed - Malignant Neoplasm Clinical Trials

Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment

Start date: July 25, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies sensory evaluation of oral nutrition supplements in patients at risk for mucositis undergoing cancer treatment. Sensory evaluation may help to obtain input about new oral nutritional supplements that may increase nutrient intake and maintain or improve nutritional status, functional capacity, and quality of life in cancer patients.

NCT ID: NCT03219502 Active, not recruiting - Malignant Neoplasm Clinical Trials

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

Start date: July 10, 2017
Phase: N/A
Study type: Interventional

This trial studies how well repetitive transcranial magnetic stimulation (rTMS) works in improving neuropathy due to oxaliplatin chemotherapy in patients with stage I-IV cancer. rTMS is designed to change brain activity by introducing small magnetic impulses to the scalp that encourage the brain to change its activity.

NCT ID: NCT03207854 Recruiting - Malignant Neoplasm Clinical Trials

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Start date: April 12, 2017
Phase:
Study type: Observational

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.

NCT ID: NCT03186638 Completed - Clinical trials for Cognitive Impairment

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

Start date: May 26, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.

NCT ID: NCT03097588 Completed - Malignant Neoplasm Clinical Trials

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Start date: April 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant. Chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan (BEAM), makes people feel sick to their stomach and causes vomiting. Netupitant and palonosetron hydrochloride may reduce the nausea and vomiting caused by the BEAM treatment.

NCT ID: NCT03067766 Completed - Malignant Neoplasm Clinical Trials

Comic Art Creation as Supportive Care in Cancer Patients and Caregivers

Start date: August 24, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well comic art creation works as supportive care in cancer patients and caregivers. Participating in a comic art creation workshop may help patients and their family members or friends share their medical experience through storytelling and drawings in a way that can, but does not have to, reflect the real world. It may also help improve emotional wellbeing and communication in cancer patients and caregivers.

NCT ID: NCT03057639 Terminated - Malignant Neoplasm Clinical Trials

Clinical Model in Evaluating Clinical, Psychosocial, and Health Economic Factors in Adolescent and Young Adult Patients With Cancer

Start date: February 3, 2017
Phase:
Study type: Observational

This research trial studies the Adolescent and Young Adult (AYA) Cancers Clinical Model in evaluating clinical, psychosocial, and health economic factors in adolescent and young adult patients with cancer. Studying the Adolescent and Young Adult Cancers Clinical Model may help doctors learn more about the effect of the AYA services on patient care, including clinical (nurse navigation), psychosocial (social work), and economic (financial) areas.

NCT ID: NCT03040726 Completed - Nausea Clinical Trials

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Start date: May 3, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.

NCT ID: NCT02988271 Active, not recruiting - Depression Clinical Trials

Meditation Therapy in Improving Anxiety and Depression in Cancer Patients With Psychosocial Distress

Start date: April 11, 2019
Phase: N/A
Study type: Interventional

This trial studies how well self-administered meditation therapy works in improving anxiety and depression in cancer patients who exhibit psychosocial distress. Meditation therapy is a mind-body approach that uses a variety of techniques, such as deep breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer.

NCT ID: NCT02978846 Completed - Malignant Neoplasm Clinical Trials

Perceptions of Side Effects of Cancer Chemoradiotherapy

Start date: June 1, 2016
Phase:
Study type: Observational

This study is asking patients who are undergoing radiation therapy with or without chemotherapy on how well they evaluate their side effects on the last day of treatment. This study is not to change health outcomes of the patients in this study. Asking patients to rank side effects in order of which ones bother them the most may help researchers identify the most troubling side effects of cancer treatment.